Yan Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yan Guo has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Jialin Wang
Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, No.1, East Jianshe Road, 450052, Zhengzhou, China
4 shared publicationsMengjun Zhang
Department of Gynecology, The Third Affiliated Hospital of Zhengzhou University, 7 Rehabilitation Front Street, Zhengzhou 450052, China
3 shared publications- Lindong Zhang
Department of Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications Zidi Zhang
Department of Gynecology, The Third Affiliated Hospital of Zhengzhou University, 7 Rehabilitation Front Street, Zhengzhou 450052, China
2 shared publicationsHaodi Yue
Department of the Clinical Research Center, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, No. 7 Weiwu Street, Zhengzhou 450003, China
1 shared publication- Haodi Yue
Department of Center for Clinical Single Cell Biomedicine, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, No. 7 Weiwu Street, Zhengzhou 450003, China
1 shared publication
Latest Publications
- 13 December 2025
- Published by Elsevier in Cellular Signalling
- Vol. 139, 112325
Unraveling the secrets of UBE2S in endometrial cancer: Potential targets for diagnosis, prognostic assessment, and ferroptosis therapy
- 13 December 2025
- Published by Elsevier in Cellular Signalling
- Vol. 139, 112325
Unraveling the secrets of UBE2S in endometrial cancer: Potential targets for diagnosis, prognostic assessment, and ferroptosis therapy
- Open Access
- 5 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (8) , 5420-5434
Mechanical forces and immune cells in the tumor microenvironment: from regulation mechanisms to therapeutic strategies
The tumor microenvironment (TME) plays a crucial regulatory role in the initiation and progression of tumors. Mechanical forces in the TME, such as matrix stiffness, solid stress, fluid shear stress, and microstructural changes, can regulate the activity, migration, and proliferation of immune cells through mechanotransduction pathways, thereby affecting the growth and immune evasion of tumor cells. However, the precise mechanisms by which mechanical forces regulate immune cells and their impact on immunotherapy are not yet fully understood. This review aims to explore how mechanical forces in the TME regulate T cells, natural killer cells, tumor-associated macrophages, B cells, neutrophils, and dendritic cells, and influence immunotherapy. Additionally, this review emphasizes the temporal effects of mechanical forces on immune cells during tumor progression and highlights the need to investigate the interactions of different mechanical forces in the TME and their combined effects on immune cells. These insights can provide a theoretical basis and research directions for optimizing future tumor treatment strategies based on mechanical regulation.
- 5 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (8) , 5420-5434
Open AccessMechanical forces and immune cells in the tumor microenvironment: from regulation mechanisms to therapeutic strategies
The tumor microenvironment (TME) plays a crucial regulatory role in the initiation and progression of tumors. Mechanical forces in the TME, such as matrix stiffness, solid stress, fluid shear stress, and microstructural changes, can regulate the activity, migration, and proliferation of immune cells through mechanotransduction pathways, thereby affecting the growth and immune evasion of tumor cells. However, the precise mechanisms by which mechanical forces regulate immune cells and their impact on immunotherapy are not yet fully understood. This review aims to explore how mechanical forces in the TME regulate T cells, natural killer cells, tumor-associated macrophages, B cells, neutrophils, and dendritic cells, and influence immunotherapy. Additionally, this review emphasizes the temporal effects of mechanical forces on immune cells during tumor progression and highlights the need to investigate the interactions of different mechanical forces in the TME and their combined effects on immune cells. These insights can provide a theoretical basis and research directions for optimizing future tumor treatment strategies based on mechanical regulation.
- Open Access
Diverse roles of UBE2S in cancer and therapy resistance: Biological functions and mechanisms
- Open Access
- 19 December 2023
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 16 (1) , 1-18
Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer
Background: Epithelial ovarian cancer (OC) is the fourth leading cause of cancer-related deaths in women, with a 5-year survival rate of 30%-50%. Platinum resistance is the chief culprit for the high recurrence and mortality rates. Several studies confirm that the metabolic regulation of ubiquitinating enzymes plays a vital role in platinum resistance in OC. Methods: In this study, we selected ubiquitin-conjugating enzyme E2S (UBE2S) as the candidate gene for validation. The levels of UBE2S expression were investigated using TCGA, GTEx, UALCAN, and HPA databases. In addition, the correlation between UBE2S and platinum resistance in OC was analyzed using data from TCGA. Cisplatin-resistant OC cell lines were generated and UBE2S was knocked down; the transfection efficiency was verified. Subsequently, the effects of knockdown of UBE2S on the proliferation and migration of cisplatin-resistant OC cells were examined through the CCK8, Ki-67 immunofluorescence, clone formation, wound healing, and transwell assays. In addition, the UBE2S gene was also validated in vivo by xenograft models in nude mice. Finally, the relationship between the UBE2S gene and autophagy and the possible underlying regulatory mechanism was preliminarily investigated through MDC and GFP-LC3-B autophagy detection and western blotting experiments. Most importantly, experimental validation of mTOR agonist reversion (the rescuse experiments) was also performed. Results: UBE2S was highly expressed in OC at both nucleic acid and protein levels. The results of immunohistochemistry showed that the level of UBE2S expression in platinum-resistant samples was significantly higher relative to the platinum-sensitive samples. By cell transfection experiments, knocking down of the UBE2S gene was found to inhibit the proliferation and migration of cisplatin-resistant OC cells. Moreover, the UBE2S gene could inhibit autophagy by activating the PI3K/AKT/mTOR signaling pathway to induce cisplatin resistance in OC in vivo and in vitro. Conclusion: In conclusion, we discovered a novel oncogene, UBE2S, which was associated with platinum response in OC, and examined its key role through bioinformatics and preliminary experiments. The findings may open up a new avenue for the evaluation and treatment of OC patients at high risk of cisplatin resistance.
- 19 December 2023
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 16 (1) , 1-18
Open AccessActivation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer
Background: Epithelial ovarian cancer (OC) is the fourth leading cause of cancer-related deaths in women, with a 5-year survival rate of 30%-50%. Platinum resistance is the chief culprit for the high recurrence and mortality rates. Several studies confirm that the metabolic regulation of ubiquitinating enzymes plays a vital role in platinum resistance in OC. Methods: In this study, we selected ubiquitin-conjugating enzyme E2S (UBE2S) as the candidate gene for validation. The levels of UBE2S expression were investigated using TCGA, GTEx, UALCAN, and HPA databases. In addition, the correlation between UBE2S and platinum resistance in OC was analyzed using data from TCGA. Cisplatin-resistant OC cell lines were generated and UBE2S was knocked down; the transfection efficiency was verified. Subsequently, the effects of knockdown of UBE2S on the proliferation and migration of cisplatin-resistant OC cells were examined through the CCK8, Ki-67 immunofluorescence, clone formation, wound healing, and transwell assays. In addition, the UBE2S gene was also validated in vivo by xenograft models in nude mice. Finally, the relationship between the UBE2S gene and autophagy and the possible underlying regulatory mechanism was preliminarily investigated through MDC and GFP-LC3-B autophagy detection and western blotting experiments. Most importantly, experimental validation of mTOR agonist reversion (the rescuse experiments) was also performed. Results: UBE2S was highly expressed in OC at both nucleic acid and protein levels. The results of immunohistochemistry showed that the level of UBE2S expression in platinum-resistant samples was significantly higher relative to the platinum-sensitive samples. By cell transfection experiments, knocking down of the UBE2S gene was found to inhibit the proliferation and migration of cisplatin-resistant OC cells. Moreover, the UBE2S gene could inhibit autophagy by activating the PI3K/AKT/mTOR signaling pathway to induce cisplatin resistance in OC in vivo and in vitro. Conclusion: In conclusion, we discovered a novel oncogene, UBE2S, which was associated with platinum response in OC, and examined its key role through bioinformatics and preliminary experiments. The findings may open up a new avenue for the evaluation and treatment of OC patients at high risk of cisplatin resistance.